Entrada Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Revenue	129.01	0	0	0	0
Gross Profit	129.01	0	0	0	0
Selling, General & Admin	32.29	30.64	15.2	5.57	3.61
Research & Development	99.88	66.61	35.93	21.1	8.22
Operating Expenses	132.18	97.25	51.13	26.67	11.82
Operating Income	-3.16	-97.25	-51.13	-26.67	-11.82
Interest Expense / Income	0	0	-0.03	0.14	0
Other Expense / Income	-15.22	-2.63	0.06	-0.29	-6.72
Pretax Income	12.06	-94.62	-51.16	-26.52	-5.1
Income Tax	18.74	0	0	0	0
Net Income	-6.69	-94.62	-51.16	-26.52	-5.1
Shares Outstanding (Basic)	33	31	6	1	7
Shares Outstanding (Diluted)	33	31	6	1	7
Shares Change	5.61%	399.27%	467.09%	-83.63%	-
EPS (Basic)	-0.20	-3.02	-8.16	-24.00	-0.76
EPS (Diluted)	-0.20	-3.02	-8.16	-24.00	-0.76
Free Cash Flow	134.19	-96.67	-55.44	-27.89	-11.43
Free Cash Flow Per Share	4.06	-3.09	-8.85	-25.23	-1.69
Gross Margin	100.00%	-	-	-	-
Operating Margin	-2.45%	-	-	-	-
Profit Margin	-5.18%	-	-	-	-
Free Cash Flow Margin	104.01%	-	-	-	-
Effective Tax Rate	155.45%	-	-	-	-
EBITDA	14.9	-92.72	-50.07	-26.05	-5
EBITDA Margin	11.55%	-	-	-	-
Depreciation & Amortization	2.84	1.9	1.12	0.33	0.1
EBIT	12.06	-94.62	-51.19	-26.38	-5.1
EBIT Margin	9.34%	-	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).